Evolving global and national criteria for identifying a suspected case of COVID-19.


Journal

The Journal of international medical research
ISSN: 1473-2300
Titre abrégé: J Int Med Res
Pays: England
ID NLM: 0346411

Informations de publication

Date de publication:
Aug 2020
Historique:
entrez: 1 9 2020
pubmed: 1 9 2020
medline: 8 9 2020
Statut: ppublish

Résumé

The outbreak of coronavirus disease 2019 (COVID-19) began in December 2019 and continues to spread worldwide. Rapid and accurate identification of suspected cases is critical in slowing spread of the virus that causes the disease. We aimed to highlight discrepancies in the various criteria used by international agencies and highly impacted individual countries around the world. We reviewed the criteria for identifying a suspected case of COVID-19 used by two international public health agencies and 10 countries across Asia, Europe, and North America. The criteria included information on the clinical causes of illness and epidemiological risk factors. Non-English language guidelines were translated into English by a co-author who is fluent in that particular language. Although most criteria are modifications of World Health Organization recommendations, the specific clinical features and epidemiological risks for triggering evaluation of patients with suspected COVID-19 differed widely among countries. The rationale for these differences may be related to each country's resources, politics, experience with previous outbreaks or pandemics, health insurance system, COVID-19 outbreak severity, and other undetermined factors. We found no consensus regarding the best diagnostic criteria for identifying a suspected case of COVID-19.

Sections du résumé

BACKGROUND BACKGROUND
The outbreak of coronavirus disease 2019 (COVID-19) began in December 2019 and continues to spread worldwide. Rapid and accurate identification of suspected cases is critical in slowing spread of the virus that causes the disease. We aimed to highlight discrepancies in the various criteria used by international agencies and highly impacted individual countries around the world.
METHODS METHODS
We reviewed the criteria for identifying a suspected case of COVID-19 used by two international public health agencies and 10 countries across Asia, Europe, and North America. The criteria included information on the clinical causes of illness and epidemiological risk factors. Non-English language guidelines were translated into English by a co-author who is fluent in that particular language.
RESULTS RESULTS
Although most criteria are modifications of World Health Organization recommendations, the specific clinical features and epidemiological risks for triggering evaluation of patients with suspected COVID-19 differed widely among countries. The rationale for these differences may be related to each country's resources, politics, experience with previous outbreaks or pandemics, health insurance system, COVID-19 outbreak severity, and other undetermined factors.
CONCLUSION CONCLUSIONS
We found no consensus regarding the best diagnostic criteria for identifying a suspected case of COVID-19.

Identifiants

pubmed: 32865095
doi: 10.1177/0300060520938943
pmc: PMC7469754
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

300060520938943

Références

Can Assoc Radiol J. 2020 May;71(2):195-200
pubmed: 32129670
Lancet. 2020 Mar 21;395(10228):945
pubmed: 32142626
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Infect Control Hosp Epidemiol. 2020 Jun;41(6):754-755
pubmed: 32192541
JAMA. 2020 Apr 14;323(14):1341-1342
pubmed: 32125371
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Infect. 2020 Apr;80(4):401-406
pubmed: 32112886

Auteurs

Amporn Atsawarungruangkit (A)

Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States.

Jin Yuan (J)

Boston University School of Medicine, Boston, Massachusetts, United States.

Takamitsu Kodama (T)

Tajimi City Hospital, Gifu, Japan.

Ming-Tai Cheng (MT)

National Taiwan University Hospital, Taipei, Taiwan.

Mohammad Mansouri (M)

Montefiore Medical Center, New York, New York, United States.

Boram Han (B)

East Boston Neighborhood Health Center, Boston, Massachusetts, United States.
Boston Medical Center, Boston, Massachusetts, United States.

Jarinrat Kongkamnerd (J)

Farmacia, Chiangmai, Thailand.

Fabian Riegg (F)

Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States.
University of Tübingen, Tübingen, Germany.

Anupama Menon (A)

Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States.

Steven F Moss (SF)

Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH